Journal ArticleOPEN ACCESS

Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities?

Molecular and Cellular Oncology (2018) 5(3)
DOI: 10.1080/23723556.2018.1441628
15Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The arginine methyltransferase PRMT5 has been increasingly associated with cancer development. Here we describe our recent findings that PRMT5 is a critical regulator of breast cancer stem cell survival via the epigenetic regulation of FOXP1. Consequently, PRMT5 inhibitors could potentially eradicate cancer stem cells thereby preventing tumour relapse.

Author supplied keywords

Cite

CITATION STYLE

APA

Chiang, K., & Davies, C. C. (2018). Linking PRMT5 to breast cancer stem cells: New therapeutic opportunities? Molecular and Cellular Oncology, 5(3). https://doi.org/10.1080/23723556.2018.1441628

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free